Outlook Therapeutics (OTLK) announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting being held January ...

Lawrence A. Kenyon, Executive Vice President, CFO and Interim CEO About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with ...

Outlook Therapeutics Inc (OTLK) stock saw a decline, ending the day at $2.19 which represents a decrease of $-0.11 or -4.78% from the prior close of $2.3. The stock opened at $2.13 and touched a low ...

Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $2.23 which represents a slight increase of $0.04 or 1.83% from the prior close of $2.19. The stock opened at $2.19 and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NDAQ:ATOS) Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of ...

Fintel reports that on January 21, 2025, Cantor Fitzgerald downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) ...

TG Therapeutics is entering 2025 with investors accustomed to a beat-and-raise guidance policy and the company needs to deliver. Learn more on TGTX stock here.

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

Fintel reports that on January 17, 2025, Wedbush downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.